ReviewChemical reviews2018
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.
Review in Chemical reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Looping forward: exploring R-loop processing and therapeutic potential.FEBS letters · 2025Review
- Targeting RNA-binding proteins with small molecules: perspectives and challenges.Frontiers in chemistry · 2025Review
- Targeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40.British journal of pharmacology · 2024Review
- The hidden architects of the genome: a comprehensive review of R-loops.Molecular biology reports · 2024Review
- NMR structures of small molecules bound to a model of a CUG RNA repeat expansion.Bioorganic & medicinal chemistry letters · 2024Review
- SMTRI: A deep learning-based web service for predicting small molecules that target miRNA-mRNA interactions.Molecular therapy. Nucleic acids · 2024Article
- NMR structures of small molecules bound to a model of an RNA CUG repeat expansion.bioRxiv : the preprint server for biology · 2024Article
- Heterobifunctional small molecules to modulate RNA function.Trends in pharmacological sciences · 2024Review
- Structural Insights into the Advances and Mechanistic Understanding of Human Dicer.Biochemistry · 2023Review
- Interrogating the Human Diplome: Computational Methods, Emerging Applications, and Challenges.Methods in molecular biology (Clifton, N.J.) · 2023Article
- MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer.World journal of surgical oncology · 2022Article
- Nuclear magnetic resonance reveals a two hairpin equilibrium near the 3'-splice site of influenza A segment 7 mRNA that can be shifted by oligonucleotides.RNA (New York, N.Y.) · 2022Article
- HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia.Molecular cell · 2022Article
- A structure-specific small molecule inhibits a miRNA-200 family member precursor and reverses a type 2 diabetes phenotype.Cell chemical biology · 2022Article
- Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022Review
- Ano1 is a Prognostic Biomarker That is Correlated with Immune Infiltration in Colorectal Cancer.International journal of general medicine · 2022Article
- Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.Journal of experimental & clinical cancer research : CR · 2021Review
- Drugging the "undruggable" microRNAs.Cellular and molecular life sciences : CMLS · 2021Review
- Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets.mSphere · 2020Article
- Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions.Nature chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rapid progress in genome sequencing technology has put us firmly into a postgenomic era. A key challenge in biomedical research is harnessing genome sequence to fulfill the promise of personalized medicine. This Review describes how genome sequencing has enabled the identification of disease-causing biomolecules and how these data have been converted into chemical probes of function, preclinical lead modalities, and ultimately U.S. Food and Drug Administration (FDA)-approved drugs. In particular, we focus on the use of oligonucleotide-based modalities to target disease-causing RNAs; small molecules that target DNA, RNA, or protein; the rational repurposing of known therapeutic modalities; and the advantages of pharmacogenetics. Lastly, we discuss the remaining challenges and opportunities in the direct utilization of genome sequence to enable design of medicines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.